If you use kratom or 7-OH products, the DEA’s latest action matters. The DEA 7-OH scheduling decision is not yet a permanent Schedule I classification.
Instead, the DEA began temporary scheduling proceedings for 7-OH above specified thresholds. On August 26, 2026, the DEA separately placed MGM-15, MGM-16, and mitragynine pseudoindoxyl into Schedule I temporarily.
The action targets manufactured and concentrated 7-OH-related opioids, not traditional botanical kratom. This blog explains the thresholds, current status, consumer impact, and next steps.
Updated September 2026: The DEA has proposed temporary scheduling of 7-OH above specified thresholds.
What Is 7-OH?
7-OH, also called 7-hydroxymitragynine, is an alkaloid linked to kratom. It naturally occurs in small quantities in the Mitragyna speciosa plant, commonly known as kratom.
The concern centers on products with much higher 7-OH levels. These include concentrated, enhanced, synthetic, and semi-synthetic 7-OH products. Such products can deliver stronger opioid-like effects than traditional kratom.
How Is 7-OH Different From Traditional Kratom?
Traditional kratom contains naturally occurring 7-OH at relatively low levels. Some newer 7-OH products contain much higher concentrations due to processing, enhancement, or the addition of 7-OH.
The product’s formulation also matters because concentrated or manufactured products can differ significantly from botanical kratom. Understanding the difference between kratom and 7-OH helps explain why the DEA focuses on certain product types.
What Was the DEA’s 7-OH Scheduling Decision?
The DEA’s July 1 announcement started temporary scheduling proceedings. The DEA sent two separate Notices of Intent to the Federal Register.
One addressed 7-OH above a specified threshold. The other addressed three related substances.
What DEA announced on July 1, 2026
The DEA announced its intent to schedule covered 7-OH substances temporarily. The announcement focused on elevated and synthetic 7-OH products.
The Federal Register published the 7-OH notice in July. That notice was a Notice of Intent, not the final order.
What Threshold Did DEA Propose?
The proposed threshold uses both concentration and product type. The main threshold is more than 0.050% 7-OH.
For certain alternative products, the proposal also uses one milligram. The table below simplifies the regulatory language.
| Covered material | Proposed threshold |
| Botanical Mitragyna speciosa material | More than 0.050% 7-OH by dry weight |
| Synthetic products | More than 0.050% or more than 1 mg 7-OH |
| Further-processed kratom products | More than 0.050% or more than 1 mg 7-OH |
These thresholds are part of the proposed temporary scheduling framework. They should not be treated as a current permanent classification.
Was 7-OH permanently placed in Schedule I?
No, the July action did not permanently place 7-OH in Schedule I. It began a temporary scheduling process under the Controlled Substances Act.
As of September, 2026, the 7-OH threshold action remains distinct. The separate temporary order now covers three related substances.
Those substances are:
- Mitragynine pseudoindoxyl
- MGM-15
- MGM-16
The separate order became effective August 26, 2026. It remains effective through August 26, 2028, unless changed earlier.
The Current Status of DEA 7-OH Scheduling Decision
For covered 7-OH, DEA issued a Notice of Intent. For the three related substances, DEA issued a temporary Schedule I order.
This means headlines saying “DEA scheduled 7-OH” need context. The July 2026 announcement began proceedings for covered 7-OH products. It did not create the same effective order as the August action.
Why Is the DEA Taking Action on 7-OH?
DEA cited public health and safety concerns surrounding concentrated 7-OH products. Federal agencies have also raised concerns about misuse and dependence.
Concerns about misuse and public safety
DEA described 7-hydroxymitragynine as having opioid-like effects and risks. It also cited concerns about products with elevated 7-OH concentrations.
The FDA has reported adverse effects linked with 7-hydroxymitragynine products. Reported effects include withdrawal symptoms, insomnia, and gastrointestinal problems.
Concentrated and enhanced 7-OH products
Some products contain 7-OH far above natural kratom levels. These products may come as tablets, gummies, powders, or liquids.
The FDA has specifically distinguished these products from ordinary kratom leaf. This difference helps explain the focus on concentrated 7-OH products.
How federal agencies describe the risks
Federal agencies have focused on potency, misuse, and uncertain product contents. FDA also states that 7-OH products lack proven safe medical use.
These concerns shape the regulatory reasoning behind the action. They do not mean every kratom product falls under federal scheduling.
What Does the DEA Decision Mean for Consumers?
The effect depends on the product’s substance, formulation, and 7-OH level. Consumers should not assume every kratom product is now federally controlled.
Does This Mean All Kratom Is Illegal?
No, the federal 7-OH proposal does not automatically make kratom illegal. The proposed threshold targets specific levels and formulations.
Botanical kratom below the proposed threshold is not covered. However, state laws can impose separate restrictions on kratom products.
Does This Affect 7-OH Products Sold Online Or In Stores?
Potentially, especially products containing elevated or synthetic 7-OH. The proposed federal action targets covered substances above its thresholds.
Product labels may not always provide enough information about formulation. Consumers should therefore avoid assuming that “kratom” means traditional leaf.
What Should Someone Do If They Regularly Use 7-OH?
People who regularly use 7-OH should discuss their use with professionals. This is especially important when stopping use causes uncomfortable symptoms.
A healthcare professional can assess withdrawal, dependence, and other concerns. They can also explain appropriate support based on individual circumstances.
7-OH Dependence, Withdrawal And Treatment
Regular 7-OH use may lead to dependence for some people.
Signs That 7-OH Use May Have Become Problematic
Possible warning signs can include changes in daily use or functioning. Withdrawal symptoms after reducing use may also signal physical dependence.
Some reported symptoms include:
- Body aches or chills
- Sweating or restlessness
- Nausea, diarrhea, or stomach discomfort
- Anxiety, irritability, or low mood
- Sleep problems
- Strong cravings
These symptoms do not establish a diagnosis on their own. A qualified professional can assess the broader pattern and impact.
Why Stopping Suddenly May Be Difficult For Some People
7-OH acts on opioid receptors, which may contribute to 7-OH withdrawal. Recent case reports describe withdrawal after high-dose, chronic use.
Available evidence remains limited and largely comes from individual case reports. More research is needed to understand 7-OH dependence and withdrawal fully.
When To Seek Professional Help
Professional support is appropriate when 7-OH use feels difficult to control. It can also help when withdrawal interferes with daily responsibilities.
Severe or concerning symptoms warrant timely medical evaluation. A qualified healthcare professional can assess your symptoms and explain appropriate next steps.
What Addiction Treatment Can Address
Addiction treatment can address substance use, withdrawal concerns, and recovery goals. Care may also address mental health needs that affect recovery.
Avisa Recovery Center provides addiction treatment and mental health treatment in New Jersey. Our services can help people address substance use concerns while working toward ongoing recovery.
What Happens Next With DEA 7-OH Scheduling?
The next step is further federal action on the proposed 7-OH threshold. The process can involve additional regulatory review before an order takes effect.
The separate Schedule I order already covers three related substances. That order applies to mitragynine pseudoindoxyl, MGM-15, and MGM-16.
Consumers should watch official DEA and Federal Register updates. Product labels and state rules may also change during this process.
Conclusion
The DEA 7-OH scheduling decision is more limited than some headlines suggest. DEA proposed temporary Schedule I treatment for covered 7-OH products. The proposal focuses on specified 7-OH levels and formulations.
It does not automatically classify all botanical kratom as Schedule I.
Separately, MGM-15, MGM-16, and mitragynine pseudoindoxyl are temporarily scheduled. Understanding this distinction can make the changing rules easier to follow.
If regular 7-OH use has become difficult to manage, support is available. Avisa Recovery Center offers addiction treatment and recovery resources for people in New Jersey.
You can verify your insurance coverage to explore your treatment options. You can also call (732) 798-7743 to speak with the Avisa Recovery Center team.
Frequently Asked Questions
Is 7-OH a Schedule I drug?
The DEA targeted 7-OH above the proposed threshold for temporary scheduling. As of September 2026, the separate Schedule I order covers three related substances.
Did the DEA ban 7-OH?
No, the July action began temporary scheduling proceedings. It did not permanently ban every 7-OH product.
Is kratom now illegal?
No, federal action does not automatically make all kratom illegal. The proposed 7-OH rule targets specific levels and formulations.
What is the DEA’s 7-OH threshold?
The main proposed threshold is more than 0.050% 7-OH. Certain products also use a threshold above 1 milligram.
What are MGM-15 and MGM-16?
MGM-15 and MGM-16 are synthetic 7-OH-related substances. DEA temporarily placed both substances into Schedule I on August 26, 2026.
